The company projects 2026 revenue of $58–62 million, reflecting 65–76% growth, with gross margins above 50%. It plans $150–160 million in operating expenses, $110–120 million in cash use and an expanded $100 million debt facility, and anticipates Europe will represent about 20% of sales. Full-year 2025 revenue reached $35.3 million, up from $22.5 million in 2024, with gross margins above 50%. Fourth-quarter net revenue rose 72% to $14.3 million, while net loss widened to $20.8 million on higher SG&A spending. Senseonics shifted global Eversense commercialization from Ascensia back to its own operations, securing full operational control and eliminating revenue sharing. PHC remains a key shareholder supporting European commercialization under transitional service agreements, with in-country operations expected to close in the second quarter. Senseonics doubled U.S. patient starts to 103% year-over-year, expanded its EonCare inserter network toward 100 providers and increased active prescribers by over 80%. It will invest $12–15 million in direct-to-consumer marketing and leverage integration with Sequel’s twiist AID system to drive adoption and retention.